to PARP or not to PARP....
“EIS-12656 selectively targets tumors with no apparent effects on normal tissues.” ....“Our clinical study will also explore combination therapies that were hindered by combinatorial toxicity in the past.”
EIS-12656, a first-in-class allosteri... - Advanced Prostate...
EIS-12656, a first-in-class allosteric inhibitor of ALC1: will soon start a phase 1 trial
Written by
Maxone73
To view profiles and participate in discussions please or .
Read more about...
2 Replies
•
Good one… how far out might this one be 5-7 years maybe?
Not what you're looking for?
You may also like...
Started Phase 1 trial - RO7656594 yesterday
Started clinical trial through Honor Health Research in Scottsdale yesterday. Day one was intense...
Ups and downs of screening for a Phase 1 trial
qualify and then to have an effective response without nasty side effects. My husband is keen to...
Phase 1 trial participation Nurix NX-1607
take part in a phase 1a safety and tolerability study of NX-1607. It aims to inhibit CBL-B (Casitas...
PSCA phase one trial 
Started PARP inhibitor Olaparib and Provenge treatment
Info about ongoing Phase III PCa trials
